查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933352

全球肺炎链球菌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量、未来预测（2026-2034）

Pneumococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

肺炎链球菌疫苗市场成长驱动因子

全球肺炎链球菌疫苗市场正经历稳定成长，这主要得益于疫苗接种意识的提高、肺炎球菌感染率的上升以及疫苗技术的不断进步。根据 Fortune Business Insights 的数据显示，2025 年全球肺炎链球菌疫苗市场规模为 88 亿美元。预计该市场将从 2026 年的 91.5 亿美元成长到 2034 年的 147.6 亿美元，预测期内复合年增长率 (CAGR) 为 6.17%。北美地区凭藉着强大的疫苗接种计划和主要疫苗生产商的存在，在 2025 年占了 29.20% 的市场占有率，成为市场主导者。

肺炎链球菌疫苗用于预防由肺炎链球菌引起的感染，该菌可导致肺炎、脑膜炎和败血症等严重疾病。葛兰素史克 (GSK plc)、默克公司 (Merck & Co., Inc.) 和赛诺菲 (Sanofi) 等知名公司持续投资研发新产品，以满足日益增长的对更广泛血清型覆盖的需求。此外，有利的政府政策和加速的监管审批也促进了市场成长。

市场动态

市场驱动因素

侵袭性肺炎链球菌疾病 (IPD) 的日益增加是市场成长的主要驱动因素。与慢性疾病、HIV 感染、人口老化和社会健康决定因素相关的病例数量不断增加，进一步提高了疫苗接种的需求。根据欧洲疾病预防控制中心 (ECDC) 的报告，欧盟/欧洲经济区 (EU/EEA) 地区 2022 年确诊的侵袭性肺炎球菌病 (IPD) 病例数预计将达到 17,700 例，凸显了该疾病负担的日益加重。医疗保健支出增加，且更重视预防而非治疗，也进一步推动了市场扩张。

市场限制因子

肺炎链球菌疫苗的生产过程仍然十分复杂，构成了一项主要限制因素。此生产流程需要针对多种肺炎链球菌血清型，并将多醣体与蛋白质载体结合，这需要专门的设施、先进的设备和高水准的技术专长。这些因素增加了生产成本，并限制了生产规模的扩大，尤其对于新兴生产商而言。

市场机会

对下一代候选疫苗研发管线的投资增加带来了巨大的成长机会。现有的结合疫苗并未涵盖所有致病血清型，这为创新留下了空间。各公司正在研发高滴度蛋白疫苗，以提供更广泛的保护。赛诺菲将于2024年12月启动PCV21的III期临床试验，并扩大与SK Biosciences的合作，显示先进疫苗具有巨大的成长潜力。

市场挑战

缺乏足够的冷藏基础设施构成了一项重大挑战，尤其是在中低收入国家。肺炎链球菌疫苗需要在2°C至8°C的温度下储存，冷链物流中断会导致疫苗降解并降低效力。报告显示，全球25%的液体疫苗因冷链故障而降解，阻碍了疫苗的有效分发。

肺炎链球菌疫苗市场趋势

一个值得注意的市场趋势是，人们越来越重视成人疫苗接种计画。肺炎链球菌疾病在65岁及以上成年人中导致较高的死亡率。政府主导的措施和更新的疫苗接种指南正在扩大成人疫苗接种覆盖率。 2024年10月，美国疾病管制与预防中心 (CDC) 将肺炎链球菌结合疫苗 (PCV) 的建议接种年龄范围扩大到所有50岁及以上的未接种疫苗的成年人，进一步推动了市场成长。

依细分市场分析

依产品类型划分，市场分为PCV13、PCV15、PCV20、PCV21、PPSV23和其他疫苗。 PCV20市占率领先，这得益于其更广泛的血清型覆盖范围和更多的核准产品。 PPSV23市占率预计将稳定成长，这主要归功于其在联合免疫接种计划中的广泛应用。

依年龄组划分，儿科市场占主导地位，这主要得益于儿童对疾病的高易感性和广泛的儿童疫苗接种计划。由于教育活动和财政支持计划，成人​​市场预计将保持稳定的复合年增长率。

依分销管道划分，由于大规模公共疫苗接种计划以及与国际组织的合作，政府供应商占市场主导地位。由于疫苗取得管道的改善，医院和零售药局也实现了强劲成长。

区域展望

北美地区凭藉先进的医疗基础设施和持续的研发投入，预计将保持领先地位，2025年市场规模为48.3亿美元，2026年为48.7亿美元。

欧洲市场占第二大占有率，这得益于快速的监管审批和积极的研究活动。

亚太地区预计将实现最快成长，这主要得益于疫苗接种计划的扩展以及价格合理的国产疫苗的开发。

拉丁美洲以及中东和非洲地区预计将实现温和成长，这主要得益于疫苗接种活动的增加和区域合作。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键洞察

  • 主要国家和地区的监管环境
  • 主要国家和地区的疫苗接种率
  • 主要国家和地区的肺炎球菌疫苗政府免疫计划
  • 小儿麻痹疫苗市场的技术进步
  • 主要产业趋势（併购、合作、新产品发表）等等）

第五章：全球肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品类型划分
    • PCV13
    • PCV15
    • PCV20
    • PCV21
    • PPSV23
    • 其他
  • 市场分析、洞察与预测：依年龄组别划分
    • 儿童
    • 成人
  • 市场分析、洞察与预测：依销售管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲肺炎链球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2025)
  • 公司简介
    • GSK plc.
    • Merck &Co., Inc.
    • Abbott
    • Sanofi
    • Pfizer
    • Inventprise
    • Vaxcyte
    • Walvax Biotechnology Co., Ltd.
    • SK Bioscience
Product Code: FBI113672

Growth Factors of pneumococcal vaccines Market

The global pneumococcal vaccines market is witnessing consistent growth, supported by increasing awareness of vaccination, rising prevalence of pneumococcal diseases, and continuous advancements in vaccine technology. According to Fortune Business Insights, the global pneumococcal vaccines market was valued at USD 8.8 billion in 2025. The market is projected to grow from USD 9.15 billion in 2026 to USD 14.76 billion by 2034, registering a CAGR of 6.17% during the forecast period. North America dominated the market with a share of 29.20% in 2025, driven by strong immunization programs and the presence of leading vaccine manufacturers.

Pneumococcal vaccines are administered to prevent infections caused by Streptococcus pneumoniae, which can lead to severe diseases such as pneumonia, meningitis, and sepsis. Established players including GSK plc., Merck & Co., Inc., and Sanofi continue to invest in pipeline development to address the rising demand for broader serotype coverage. Additionally, favorable government policies and accelerated regulatory approvals are strengthening market growth.

Market Dynamics

Market Drivers

The increasing prevalence of invasive pneumococcal diseases (IPD) is a key driver of market growth. Rising cases associated with chronic illnesses, HIV infections, aging populations, and social determinants of health have intensified the need for preventive vaccination. The European Centre for Disease Prevention and Control reported 17,700 confirmed IPD cases in the EU/EEA in 2022, highlighting the growing disease burden. Increased healthcare expenditure focused on prevention rather than treatment further supports market expansion.

Market Restraints

The complexity of pneumococcal vaccine manufacturing remains a significant restraint. The production process involves targeting multiple pneumococcal serotypes and conjugating polysaccharides to protein carriers, which requires specialized facilities, advanced equipment, and high technical expertise. These factors increase manufacturing costs and limit scalability, particularly for emerging manufacturers.

Market Opportunities

Rising investment in next-generation pipeline candidates presents substantial growth opportunities. Existing conjugate vaccines do not cover all disease-causing serotypes, leaving room for innovation. Companies are developing higher-valent and protein-based vaccines to provide broader protection. In December 2024, Sanofi initiated a Phase 3 program for PCV21 and expanded collaboration with SK Bioscience, underlining strong growth potential for advanced vaccines.

Market Challenges

The lack of adequate cold storage infrastructure poses a major challenge, especially in low- and middle-income countries. Pneumococcal vaccines require storage between 2°C and 8°C, and disruptions in cold chain logistics can lead to vaccine spoilage and reduced efficacy. Reports indicate that 25% of liquid vaccines are spoiled globally due to cold chain failures, hampering effective distribution.

Pneumococcal Vaccines Market Trends

A notable trend in the market is the increasing focus on adult vaccination programs. Pneumococcal diseases cause high mortality among adults aged 65 years and older. Government initiatives and updated vaccination guidelines are expanding adult immunization coverage. In October 2024, the U.S. CDC expanded age-based PCV recommendations to include all PCV-naive adults aged 50 years and above, supporting market growth.

Segmentation Analysis

By product type, the market is segmented into PCV13, PCV15, PCV20, PCV21, PPSV23, and others. The PCV20 segment holds a leading share, driven by broader serotype coverage and increasing approvals. The PPSV23 segment is expected to grow steadily due to its widespread use in combination immunization schedules.

By age group, the pediatric segment dominates the market, supported by high disease susceptibility in children and extensive childhood immunization programs. The adult segment is expected to grow at a stable CAGR, driven by awareness initiatives and financial support programs.

By distribution channel, government suppliers dominate the market, owing to large-scale public immunization programs and collaborations with global organizations. Hospital and retail pharmacies are also witnessing strong growth due to improved accessibility.

Regional Outlook

North America led the market with a valuation of USD 4.83 billion in 2025 and USD 4.87 billion in 2026, supported by advanced healthcare infrastructure and continuous R&D investments.

Europe holds the second-largest share, driven by fast-track regulatory approvals and strong research activity.

Asia Pacific is projected to register the fastest growth, supported by expanding immunization programs and development of affordable indigenous vaccines.

Latin America and the Middle East & Africa are expected to grow moderately due to increasing vaccination drives and regional collaborations.

Competitive Landscape

The global pneumococcal vaccines market is semi-consolidated, with key players such as Sanofi, Merck & Co., Inc., GSK plc., Pfizer, and Abbott holding significant market shares. These companies focus on strategic expansions, regulatory approvals, and pipeline advancements. Emerging players including Vaxcyte, Inventprise, and Walvax Biotechnology are also strengthening their presence through clinical development and partnerships.

Conclusion

The global pneumococcal vaccines market is positioned for steady growth over the forecast period, supported by rising disease prevalence, expanding immunization programs, and continuous innovation in higher-valent vaccine development. With the market valued at USD 8.8 billion in 2025, projected to reach USD 9.15 billion in 2026 and USD 14.76 billion by 2034, strong government support, pipeline expansion, and growing focus on both pediatric and adult vaccination are expected to drive long-term market expansion despite challenges related to manufacturing complexity and cold chain infrastructure.

Segmentation

By Product Type

  • PCV13
  • PCV15
  • PCV20
  • PCV21
  • PPSV23
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Product Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product Type, Age Group, Distribution Channel, and Country)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Pneumococcal Vaccines- By Key Countries/ Regions
  • 4.4. Technological Advancements in Polio Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. PCV13
    • 5.1.2. PCV15
    • 5.1.3. PCV20
    • 5.1.4. PCV21
    • 5.1.5. PPSV23
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Pediatric
    • 5.2.2. Adults
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. PCV13
    • 6.1.2. PCV15
    • 6.1.3. PCV20
    • 6.1.4. PCV21
    • 6.1.5. PPSV23
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Pediatric
    • 6.2.2. Adults
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. PCV13
    • 7.1.2. PCV15
    • 7.1.3. PCV20
    • 7.1.4. PCV21
    • 7.1.5. PPSV23
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Pediatric
    • 7.2.2. Adults
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. PCV13
    • 8.1.2. PCV15
    • 8.1.3. PCV20
    • 8.1.4. PCV21
    • 8.1.5. PPSV23
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Pediatric
    • 8.2.2. Adults
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. PCV13
    • 9.1.2. PCV15
    • 9.1.3. PCV20
    • 9.1.4. PCV21
    • 9.1.5. PPSV23
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Pediatric
    • 9.2.2. Adults
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. PCV13
    • 10.1.2. PCV15
    • 10.1.3. PCV20
    • 10.1.4. PCV21
    • 10.1.5. PPSV23
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Pediatric
    • 10.2.2. Adults
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products Types
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products Types
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products Types
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products Types
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer
      • 11.2.5.1. Overview
      • 11.2.5.2. Products Types
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Inventprise
      • 11.2.6.1. Overview
      • 11.2.6.2. Products Types
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Vaxcyte
      • 11.2.7.1. Overview
      • 11.2.7.2. Products Types
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Walvax Biotechnology Co., Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products Types
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. SK Bioscience
      • 11.2.9.1. Overview
      • 11.2.9.2. Products Types
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 7: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 9: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 11: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 13: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 15: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 17: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 22: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Pneumococcal Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Pneumococcal Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 7: North America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 9: North America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 10: North America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Pneumococcal Vaccines Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Pneumococcal Vaccines Market Value Share (%), by Country, 2025
  • Figure 14: Europe Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 15: Europe Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 17: Europe Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 18: Europe Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 21: Europe Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 22: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 30: Latin America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 31: Latin America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 32: Latin America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 33: Latin America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 34: Latin America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 37: Latin America Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 38: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 39: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 40: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 41: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 42: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 46: Global Pneumococcal Vaccines Market Share (%), by Company, 2025